Intuitive Surgical, Inc. (NASDAQ:ISRG) Short Interest Update

Intuitive Surgical, Inc. (NASDAQ:ISRG) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 3,850,000 shares, an increase of 5.5% from the May 15th total of 3,650,000 shares. Based on an average daily volume of 1,370,000 shares, the days-to-cover ratio is currently 2.8 days.

Insider Activity at Intuitive Surgical

In other news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares in the company, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total transaction of $589,484.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,956 shares of company stock worth $6,927,011. 0.80% of the stock is currently owned by company insiders.

Institutional Trading of Intuitive Surgical

Institutional investors have recently bought and sold shares of the business. Provence Wealth Management Group bought a new position in shares of Intuitive Surgical in the fourth quarter worth $276,000. Portside Wealth Group LLC increased its holdings in Intuitive Surgical by 8.2% in the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 62 shares during the period. Sequoia Financial Advisors LLC raised its position in shares of Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares in the last quarter. Public Employees Retirement System of Ohio lifted its holdings in shares of Intuitive Surgical by 5.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after acquiring an additional 9,869 shares during the period. Finally, HCR Wealth Advisors boosted its position in shares of Intuitive Surgical by 26.3% during the 4th quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after acquiring an additional 217 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 0.6 %

Shares of NASDAQ:ISRG traded up $2.62 during trading on Tuesday, reaching $432.62. 131,654 shares of the stock were exchanged, compared to its average volume of 1,487,810. The firm has a market cap of $153.45 billion, a PE ratio of 77.62, a PEG ratio of 5.50 and a beta of 1.39. The stock has a 50-day moving average price of $393.56 and a 200-day moving average price of $375.72. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $433.79.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the business earned $1.00 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. On average, sell-side analysts expect that Intuitive Surgical will post 4.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Piper Sandler lifted their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. Citigroup boosted their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus lifted their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, BTIG Research increased their price target on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $403.67.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.